Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...

Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a ...

No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...

Equities research analysts at William Blair lowered their FY2025 earnings per share estimates for shares of Zealand Pharma A/S in a research note issued to investors on Wednesday, March 12th. William ...

Amidst a backdrop of global trade policy uncertainty and mixed economic signals, the European market has shown resilience, with Germany's DAX Index rising by over 2% despite broader concerns impacting ...

Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker ...

Viking Therapeutics (VKTX) stock gains as Roche (RHHBY) and Zealand Pharma's (ZLDPF) $5.3B deal for obesity drugs lifts ...

Roche (RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and ...

Shares of ZLDPF stock opened at $97.78 on Thursday. The company has a market cap of $6.94 billion, a PE ratio of -41.43 and a beta of 0.88. The company has a current ratio of 35.49, a quick ratio ...